Rapamycin impairs UV induction of mutant-p53 overexpressing cell clusters without affecting tumor onset

International Journal of Cancer

Volumn 131, Issue 6, 2012, Pages 1267-1276

  Voskamp, P ^a   Bodmann, C A ^a   Rebel, H G ^a   Koehl, G E ^b   Tensen, C P ^a   Bouwes Bavinck, J N ^a   El Ghalbzouri, A ^a   Van Kranen, H J ^c   Willemze, R ^a   Geissler, E K ^b   De Gruijl, F R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

apoptosis; HIF1 ; immunosuppressant; p53 mutations; precursor lesions; rapamycin; squamous cell carcinoma; UV carcinogenesis

Indexed keywords

CASPASE 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUTANT PROTEIN; PROTEIN P53; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; FRAMESHIFT MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; SKIN TUMOR; TUMOR CELL; ULTRAVIOLET RADIATION; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; GENES, P53; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, HAIRLESS; MUTATION; NEOPLASMS, RADIATION-INDUCED; SIROLIMUS; ULTRAVIOLET RAYS;

EID: 84864145380     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27391     Document Type: Article

References (27)

1. Ingvar A, Smedby KE, Lindelöf B, Fernberg P, Bellocco R, Tufveson G, Höglund P, Adami J,. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol Dial Transplant 2010; 25: 2764-71.
2. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP,. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-8.
3. Salgo R, Gossmann J, Schöfer H, Kachel HG, Kuck J, Geiger H, Kaufmann R, Scheuermann EH,. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10: 1385-93.
4. Hollander MC, Blumenthal GM, Dennis PA,. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011; 11: 289-301.
5. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch K-W, Geissler EK,. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35.
6. Wunderlich L, Paragh G, Wikonkal NM, Banhegyi G, Karpati S, Mandl J,. UVB induces a biphasic response of HIF-1α in cultured human keratinocytes. Exp Dermatol 2008; 17: 335-42.
7. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ,. p53/p21CIP1 Cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin. Cancer Res 2001; 61: 3373-81.
8. Wulff BC, Kusewitt DF, van Buskirk AM, Thomas-Ahner JM, Duncan FJ, Oberyszyn TM,. Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. J Invest Dermatol 2008; 128: 2467-73.
9. de Gruijl FR, Koehl GE, Voskamp P, Strik A, Rebel HG, Gaumann A, de Fijter JW, Tensen CP, Bavinck JN, Geissler EK,. Early and late effects of the immunosuppressants rapamycin and mycophenolate mofetil on UV carcinogenesis. Int J Cancer 2010; 127: 796-804.
10. Neklesa TK, Davis RW,. Superoxide anions regulate TORC1 and its ability to bind Fpr1:rapamycin complex. Proc Natl Acad Sci USA 2008; 105: 15166-71.
11. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, Leffell DJ, Tarone RE, Brash DE,. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996; 93: 14025-9.
12. Rebel H, Kram N, Westerman A, Banus S, van Kranen HJ, de Gruijl FR,. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice. Carcinogenesis 2005; 26: 2123-30.
13. Kramata P, Lu Y-P, Lou Y-R, Singh RN, Kwon SM, Conney AH,. Patches of mutant p53-immunoreactive epidermal cells induced by chronic UVB irradiation harbor the same p53 mutations as squamous cell carcinomas in the skin of hairless SKH-1 mice. Cancer Res 2005; 65: 3577-85.
14. Ren ZP, Ponten F, Nister M, Ponten J,. Two distinct p53 immunohistochemical patterns in human squamous-cell skin cancer, precursors and normal epidermis. Int J Cancer 1996; 69: 174-9.
15. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T,. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-60.
16. de Vries A, Flores ER, Miranda B, Hsieh H-M, van Oostrom CTM, Sage J, Jacks T,. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 2002; 99: 2948-53.
17. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004; 5: 375-87.
18. El-Ghalbzouri A, Gibbs S, Lamme E, van Blitterswijk CA, Ponec M,. Effect of fibroblasts on epidermal regeneration. Br J Dermatol 2002; 147: 230-43.
19. Krotz F, Keller M, Derflinger S, Schmid H, Gloe T, Bassermann F, Duyster J, Cohen CD, Schuhmann C, Klauss V, Pohl U, Stempfle H-U, et al. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension 2007; 49: 201-8.
20. van Kranen HJ, Westerman A, Berg RJW, Kram N, van Kreijl CF, Wester PW, de Gruijl FR,. Dose-dependent effects of UVB-induced skin carcinogenesis in hairless p53 knockout mice. Mutat Res 2005; 571: 81-90.
21. Berg RJ, van Kranen HJ, Rebel HG, de Vries A, van Vloten WA, van Kreijl CF, van der Leun JC, de Gruijl FR,. Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells. Proc Natl Acad Sci USA 1996; 93: 274-8.
22. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT,. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004-14.
23. Rebel H, Mosnier LO, Berg RJW, Vries AW-d, van Steeg H, van Kranen HJ, de Gruijl FR,. Early p53-positive foci as indicators of tumor risk in ultraviolet-exposed hairless mice: kinetics of induction, effects of DNA repair deficiency, and p53 heterozygosity. Cancer Res 2001; 61: 977-83.
24. Wang GL, Jiang BH, Rue EA, Semenza GL,. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-4.
25. Rezvani HR, Dedieu S, North S, Belloc F, Rossignol R, Letellier T, de Verneuil H, Taieb A, Mazurier F,. Hypoxia-inducible factor-1[α], a key factor in the keratinocyte response to UVB exposure. J Biol Chem 2007; 282: 16413-22.
26. Piret JP, Mottet D, Raes M, Michiels C,. Is HIF-1α a pro- or an anti-apoptotic protein? Biochem Pharmacol 2002; 64: 889-92.
27. Greijer AE, van der Wall E,. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004; 57: 1009-14.